![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Amends In-Vivo Option for Showing Bioequivalence to Durezol
FDA Amends In-Vivo Option for Showing Bioequivalence to Durezol
![](https://www.fdanews.com/ext/resources/test/Drug-Images/red-orange-capsules.gif?t=1433870463&width=430)
February 22, 2017
The FDA revised its recommendations for in vivo studies intended to show bioequivalence to Durezol (difluprednate), and asked that generics makers now measure the active metabolite 9-difluoroprednisolone 17-butyrate.
Previous guidance advised sponsors to only measure the active ingredient, difluprednate, when conducting in vivo studies to show bioequivalence.
The revision comes after Alcon and Novartis petitioned the FDA to apply stricter requirements on bioequivalence studies intended to supplement applications for Durezol generics. The FDA approved the petition in part, but denied the request to remove the in vivo study option from the guidance.
Upcoming Events
-
21Oct